FDA cited Zhejiang Gaorong Cosmetic for OTC drug CGMP violations in component testing and quality unit oversight.
What happened
FDA reviewed records the company submitted after FDA's January 20, 2026, request under section 704(a)(4) of the FD&C Act; this was a records review, not an inspection. FDA found the company did not adequately test incoming components for identity and impurities, relied on supplier certificates of analysis without establishing their reliability, and did not ensure its quality unit adequately oversaw manufacturing and stability data. FDA also said all drugs from the firm were placed on Import Alert 66-40 on July 31, 2026.
What FDA found
The firm did not show it tested each incoming component lot for identity before use in manufacturing.
21 CFR 211.84(d)(1)The firm relied on supplier certificates of analysis for active ingredients without validating the supplier's test methods or establishing their reliability at appropriate intervals.
21 CFR 211.84(d)(2)The firm's quality unit did not effectively approve or reject materials and products or oversee quality, including complete batch records and stability data to support expiry.
21 CFR 211.22(a)
What FDA wants
FDA asks for a written response within 15 business days that includes corrective actions, a risk assessment and testing of high-risk components (with retain testing results due within 30 calendar days), quality-unit remediation, and a material-system review. FDA also recommends engaging a qualified CGMP consultant.
Who should pay attention
- U.S. importers and distributors of the firm's OTC drugs
- brands that buy OTC drugs or cosmetics from this contract manufacturer
- companies relying on supplier certificates of analysis for high-risk ingredients
This is a summary. Read the original letter on fda.gov.